| Cover and Content | |
| 1-4 |
| Clinical And Cost Efficacy Of Immunotherapy As A First Line Of Treatment Of Nonsquamous Metastatic Non-Small-Cell Lung Cancer | |
| Toni Vekov, Nadia Veleva, Valentina Belcheva, Jivko Kolev | 5-10 |
| Negative Opinion Of The EMA – Overview On Marketing Authorization Procedures Concluded With Rejection In 2018-2019 | |
| Violeta Getova | 11-17 |
| Genetics Of Gluten Intolerance | |
| Olga Antonova | 18-24 |
| Application Of A Physiologically-Based Pharmacokinetic (PBPK) Model In Predicting Drug Interactions | |
| Maya Radeva-Ilieva, Kaloyan Georgiev | 25-32 |
| Interactions Between Herbs And Drugs At The Level Of Сytochrome P450 | |
| Iliana Yaneva, Tatyana Karanesheva, Valentin Balabanski, Valentina Belcheva | 33-41 |
| Management Of Oral Anticoagulation In Patients, Undergoing Elective Surgery Or Invasive Procedures | |
| Antoniya Kisheva, Aylin Hadjiveli | 42-48 |
| Possibilities For Conducting Treatment With Unauthorized Medicinal Products In Bulgaria | |
| Yoana Sotirova, Svilen Issaev, Evgeni Grigorov | 49-57 |
| Medication practice in hospitals: are nanosimilars evaluated and substituted correctly? | |
| Josefien Knoeff, Beat Flühmann, Stefan Mühlebach | 58-66 |
| Legislation On The Preparation Of Medicinal Products In European Pharmacies And The Council Of Europe Resolution | |
| H PA Scheepers, J Langedijk, V Neerup Handlos, S Walser, M H Schutjens, C Neef | 67-75 |